Literature DB >> 28301271

Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016).

Yunfeng Lai1, Ruibing Wang1, Xin Chen1, Daisheng Tang2, Yuanjia Hu1, Jing Cai1, Qingwen Zhang1, Hao Hu1.   

Abstract

This article aims to explore the intellectual landscape of the study of monoclonal antibody (mAb), mainly to identify thematic trends, landmark articles and emerging trends involving mAb. This work is based on 4 sets of bibliographic records retrieved from the Web of Science. The final data set, consisting of 7,385 bibliographic records, was combined from the 4 individual data sets. This study explores the document co-citation clusters of 7,385 bibliographic records to identify the origin of mAb and the hot research specialty of this domain by applying CiteSpace software. We examined the mAb evolution from 4 perspectives: (1) Clusters of cited references regarding mAb; (2) Cited authors as contributors to mAb research; (3) Institutions participating in mAb research; and (4) Cited journals regarding mAb. The technical development, drug development and clinical applications of mAbs were analyzed. Through data analysis, we have identified the new directions for the exploration of mAbs, interactions between mAb technologies and diseases, and evolving global collaboration among institutions.

Keywords:  CiteSpace; intellectual landscape; mAb; monoclonal antibody; scientometric

Mesh:

Substances:

Year:  2017        PMID: 28301271      PMCID: PMC5489293          DOI: 10.1080/21645515.2017.1286433

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  62 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Authors:  Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

3.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

4.  Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody.

Authors:  D M Herlyn; Z Steplewski; M F Herlyn; H Koprowski
Journal:  Cancer Res       Date:  1980-03       Impact factor: 12.701

5.  Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease.

Authors:  E J Breese; C A Michie; S W Nicholls; S H Murch; C B Williams; P Domizio; J A Walker-Smith; T T MacDonald
Journal:  Gastroenterology       Date:  1994-06       Impact factor: 22.682

6.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy.

Authors:  Svetlana O Doronina; Brian E Toki; Michael Y Torgov; Brian A Mendelsohn; Charles G Cerveny; Dana F Chace; Ron L DeBlanc; R Patrick Gearing; Tim D Bovee; Clay B Siegall; Joseph A Francisco; Alan F Wahl; Damon L Meyer; Peter D Senter
Journal:  Nat Biotechnol       Date:  2003-06-01       Impact factor: 54.908

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.

Authors:  Mikkel Wandahl Pedersen; Helle Jane Jacobsen; Klaus Koefoed; Adam Hey; Charles Pyke; John Sørensen Haurum; Michael Kragh
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

9.  Production and characterization of two human glioma xenograft-localizing monoclonal antibodies.

Authors:  C J Wikstrand; R E McLendon; D E Bullard; P Fredman; L Svennerholm; D D Bigner
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

Review 10.  Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.

Authors:  Pernelle Lavaud; Fabrice Andre
Journal:  BMC Med       Date:  2014-08-12       Impact factor: 8.775

View more
  4 in total

1.  Trends involving monoclonal antibody (mAb) research and commercialization: A scientometric analysis of IMS Lifecycle R&D Focus Database (1980-2016).

Authors:  Yunfeng Lai; Sizhuo Suo; Ruibing Wang; Xiangjun Kong; Yuanjia Hu; Daisheng Tang; Honghao Shi; Shengqi Chen; Hao Hu
Journal:  Hum Vaccin Immunother       Date:  2018-01-23       Impact factor: 3.452

2.  Comparative analytical profiling of bevacizumab biosimilars marketed in India: a national control laboratory study.

Authors:  Anu Prakash; Nripendra N Mishra; Utpreksha Vaish; Sonia Sharma; Apoorva Anand; Richi V Mahajan; J P Prasad; Subhash Chand
Journal:  3 Biotech       Date:  2020-11-09       Impact factor: 2.406

3.  Western Blotting with Solutions containing Nanoliter Volumes of Antibody.

Authors:  David A Cruz Walma; Joshua W Collins
Journal:  Curr Protoc Cell Biol       Date:  2019-09

4.  Bibliometric analysis of hotspots and frontiers in cancer-related fatigue among ovarian cancer survivors.

Authors:  Yuanxia Liu; Qianxia Liu; Xiaolian Jiang
Journal:  PLoS One       Date:  2022-09-22       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.